As the battle against the deadly SARS-CoV-2 virus continues, researchers are relying on analytical laboratory techniques like chromatography to provide effective and efficient methods for characterizing the virus, as well as to analyze potential vaccines and anti-COVID-19 compounds.  

Researchers have demonstrated the utility of proteomics in the analysis of seven aggressive cancers among a cohort of nearly 800 patient samples. The analysis, published in Oncogene on February 24, reveals potentially novel therapeutic targets.  

The recombinant, soluble form of a protein that acts as the receptor for SARS-CoV-2 – the angiotensin-converting enzyme 2（ACE2）protein -- shows promise as a treatment therapy for COVID-19, according to new research presented at this week's European Congress of Radiology meeting held March 3-7.  

As the battle against the deadly SARS-CoV-2 virus continues, researchers are relying on analytical laboratory techniques like chromatography to provide effective and efficient methods for characterizing the virus, as well as to analyze potential vaccines and anti-COVID-19 compounds.  

Resilience is building its North American presence for biologics manufacturing through the acquisition of two commercial manufacturing facilities, one in Boston, and the other in Mississauga, Ontario, Canada.  

Biosero and Celltrio are integrating technologies to accelerate cell line culturing and harvesting processes, including cryogenic storage, into a modular end-to-end system.  

Researchers have identified protein compounds that are potent inhibitors of the SARS-CoV-2 main protein, a key enzyme that enables the replication of the deadly virus. Their screening and synthetic chemistry approach was detailed in an article published March 3 in Angewandte Chemie.  

Biogen is planning to build a new manufacturing facility spanning 175,000 sq ft at its base in Research Triangle Park, NC, to support development of its pipeline of gene therapies.  

Contract development and manufacturing organization Fujifilm Diosynth Biotechnologies held a ceremony on March 3 to celebrate the large-scale expansion of cell culture capacity at its production facility in Hillerød, Denmark.  

Amgen has agreed to acquire Five Prime Therapeutics for approximately $1.9 billion, adding Five Prime's pipeline of therapeutic antibodies to its oncology portfolio.  

Research firm Strategic Directions International, a sister company of ScienceBoard, projects more than $69 billion in 2021 sales for laboratory analytical and life science instrumentation businesses in a new global report.  

Researchers have demonstrated the utility of proteomics in the analysis of seven aggressive cancers among a cohort of nearly 800 patient samples. The analysis, published in Oncogene on February 24, reveals potentially novel therapeutic targets.  

The recombinant, soluble form of a protein that acts as the receptor for SARS-CoV-2 – the angiotensin-converting enzyme 2（ACE2）protein -- shows promise as a treatment therapy for COVID-19, according to new research presented at this week's European Congress of Radiology meeting held March 3-7.  

Contract research organizations（CROs）are modernizing and speeding up clinical trials with 90% unifying their clinical operations, according to a new report from Veeva Systems.  

The U.S. Patent and Trademark Office has awarded Humanigen two patents for the use of lenzilumab.  

Amunix Pharmaceuticals has raised $117 million in financing to fund the advancement of its lead T-cell engager candidate into the clinic.  

ALX Oncology Holdings and Tallac Therapeutics are joining forces to develop, manufacture, and commercialize a novel class of cancer immunotherapeutics.  

Beckman Coulter Life Sciences has launched its Cytoflex SRT benchtop cell sorter that features expanded laser and color options.